CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...
Phase 1
Nashville, Tennessee, United States and 7 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Nashville, Tennessee, United States and 73 other locations
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Nashville, Tennessee, United States and 66 other locations
This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This stu...
Phase 1, Phase 2
Nashville, Tennessee, United States and 26 other locations
administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) admin...
Phase 1, Phase 2
Nashville, Tennessee, United States and 12 other locations
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...
Phase 1
Nashville, Tennessee, United States and 29 other locations
in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).Part 2: Cohort Expansion. The...
Phase 1, Phase 2
Nashville, Tennessee, United States and 25 other locations
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin...
Phase 1, Phase 2
Nashville, Tennessee, United States and 3 other locations
This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...
Phase 2
Nashville, Tennessee, United States and 18 other locations
gemcitabine, and oxaliplatin (R-GemOx).To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma...
Phase 1, Phase 2
Nashville, Tennessee, United States and 19 other locations
Clinical trials
Research sites
Resources
Legal